TY - JOUR AU - Binswanger, I. A. AU - Kral, A. H. AU - Blumenthal, R. N. AU - Rybold, D. J. AU - Edlin, B. R. PY - 2000 DA - 2000// TI - High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco JO - Clin Infect Dis VL - 30 UR - https://doi.org/10.1086/313703 DO - 10.1086/313703 ID - Binswanger2000 ER - TY - JOUR AU - Morrison, A. AU - Elliott, L. AU - Gruer, L. PY - 1997 DA - 1997// TI - Injecting-related harm and treatment-seeking behaviour among injecting drug users JO - Addiction. VL - 92 UR - https://doi.org/10.1111/j.1360-0443.1997.tb02853.x DO - 10.1111/j.1360-0443.1997.tb02853.x ID - Morrison1997 ER - TY - JOUR AU - Phillips, K. T. AU - Stein, M. D. PY - 2010 DA - 2010// TI - Risk practices associated with bacterial infections among injection drug users in Denver, CO JO - Am J Alcohol Abuse VL - 36 UR - https://doi.org/10.3109/00952991003592311 DO - 10.3109/00952991003592311 ID - Phillips2010 ER - TY - JOUR AU - Miller, A. C. AU - Polgreen, P. M. PY - 2019 DA - 2019// TI - Many opportunities to record, diagnose, or treat injection-drug related infections are missed: a population-based cohort study of inpatient and emergency department settings JO - Clin Infect Dis VL - 68 UR - https://doi.org/10.1093/cid/ciy632 DO - 10.1093/cid/ciy632 ID - Miller2019 ER - TY - JOUR AU - Song, J. Y. AU - Safaeian, M. AU - Strathdee, S. A. AU - Vlahov, D. AU - Celentano, D. D. PY - 2000 DA - 2000// TI - The prevalence of homelessness among injection drug users with and without HIV infection JO - J Urban Health VL - 77 UR - https://doi.org/10.1007/BF02344031 DO - 10.1007/BF02344031 ID - Song2000 ER - TY - JOUR AU - Linton, S. L. AU - Celentano, D. D. AU - Kirk, G. D. AU - Mehta, S. H. PY - 2013 DA - 2013// TI - The longitudinal association between homelessness, injection drug use, and injection-related risk behavior among persons with a history of injection drug use in Baltimore, MD JO - Drug Alcohol Depend VL - 132 UR - https://doi.org/10.1016/j.drugalcdep.2013.03.009 DO - 10.1016/j.drugalcdep.2013.03.009 ID - Linton2013 ER - TY - JOUR AU - Buehrle, D. J. AU - Shields, R. K. AU - Shah, N. AU - Shoff, C. AU - Sheridan, K. PY - 2017 DA - 2017// TI - Risk factors associated with outpatient parenteral antibiotic therapy program failure among intravenous drug users JO - Open Forum Infect Dis VL - 4 UR - https://doi.org/10.1093/ofid/ofx102 DO - 10.1093/ofid/ofx102 ID - Buehrle2017 ER - TY - JOUR AU - Eaton, E. F. AU - Matthew, R. E. AU - Lane, P. S. PY - 2019 DA - 2019// TI - A 9-point risk assessment for patients who inject drugs and require intravenous antibiotics: focusing inpatient resources on patients at greatest risk of ongoing drug use JO - Clin Infect Dis VL - 68 UR - https://doi.org/10.1093/cid/ciy722 DO - 10.1093/cid/ciy722 ID - Eaton2019 ER - TY - BOOK PY - 2019 DA - 2019// TI - Orbactiv (Oritavancin) injection PB - Melinta Therapeutics CY - Lincolnshire ID - ref9 ER - TY - JOUR AU - Jones, R. N. AU - Moeck, G. AU - Arhin, F. F. AU - Dudley, M. N. AU - Rhomberg, P. R. AU - Mendes, R. E. PY - 2016 DA - 2016// TI - Results from oritavancin resistance surveillance programs (2011 to 2014): clarification for using vancomycin as a surrogate to infer oritavancin susceptibility JO - Antimicrob Agents Chemother VL - 60 UR - https://doi.org/10.1128/AAC.03029-15 DO - 10.1128/AAC.03029-15 ID - Jones2016 ER - TY - JOUR AU - Naranjo, C. A. PY - 1981 DA - 1981// TI - A method of estimating the probability of adverse drug reactions JO - Clin Pharmacol Ther VL - 30 UR - https://doi.org/10.1038/clpt.1981.154 DO - 10.1038/clpt.1981.154 ID - Naranjo1981 ER - TY - JOUR AU - Stewart, C. L. AU - Turner, M. S. AU - Frens, J. J. AU - Snider, C. B. AU - Smith, J. R. PY - 2017 DA - 2017// TI - Real-world experience with oritavancin therapy in invasive gram-positive infections JO - Infect Dis Ther VL - 6 UR - https://doi.org/10.1007/s40121-017-0156-z DO - 10.1007/s40121-017-0156-z ID - Stewart2017 ER - TY - JOUR AU - Brownell, L. E. AU - Adamsick, M. L. AU - McCreary, E. PY - 2020 DA - 2020// TI - Clinical outcomes and economic impact of oritavancin for gram-positive infections: a single academic medical center health system experience JO - Drugs – Real World Outcomes VL - 7 UR - https://doi.org/10.1007/s40801-020-00192-w DO - 10.1007/s40801-020-00192-w ID - Brownell2020 ER - TY - JOUR AU - Morrisette, T. AU - Miller, M. A. AU - Montague, B. T. AU - Barber, G. R. AU - McQueen, R. B. AU - Krsak, M. PY - 2019 DA - 2019// TI - Long-acting lipoglycopeptides: “lineless antibiotics” for serious infections in persons you use drugs JO - Open Forum Infect Dis VL - 6 UR - https://doi.org/10.1093/ofid/ofz274 DO - 10.1093/ofid/ofz274 ID - Morrisette2019 ER - TY - JOUR AU - Bork, J. T. AU - Heil, E. L. AU - Berry, S. PY - 2019 DA - 2019// TI - Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections JO - Infect Dis Ther VL - 8 UR - https://doi.org/10.1007/s40121-019-0247-0 DO - 10.1007/s40121-019-0247-0 ID - Bork2019 ER - TY - JOUR AU - Bryson-Cahn, C. AU - Beieler, A. M. AU - Chan, J. D. AU - Harrington, R. D. AU - Dhanireddy, S. PY - 2019 DA - 2019// TI - Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population JO - Open Forum Infect Dis VL - 6 UR - https://doi.org/10.1093/ofid/ofz028 DO - 10.1093/ofid/ofz028 ID - Bryson-Cahn2019 ER - TY - BOOK PY - 2018 DA - 2018// TI - Dalvance (Dalbavancin) injection PB - Allergan USA, Inc. CY - Madison ID - ref17 ER -